Background The decreased incidence of coronary artery disease observed in postmenopausal women given estrogen (E2) replacement demonstrates an atheroprotective effect of E2 that is generally believed to be mediated by indirect, E2-induced changes in cardiovascular risk factor profiles. We hypothesized that the atheroprotective effect of E2 may be in part mediated by a direct effect of E2 on vascular smooth muscle cells (VSMCs). Therefore, a series of experiments was performed to determine whether human VSMCs contain a competent E2 receptor, a ligand-activated transcription factor known to mediate E2-induced effects in nonvascular cells.
Human Vascular Smooth Muscle Cells Contain Functional Estrogen Receptor
Richard H. Karas, MD, PhD; Bruce L. Patterson, MD; Michael E. Mendelsohn, MD Background The decreased incidence of coronary artery disease observed in postmenopausal women given estrogen (E2) replacement demonstrates an atheroprotective effect of E2 that is generally believed to be mediated by indirect, E2-induced changes in cardiovascular risk factor profiles. We hypothesized that the atheroprotective effect of E2 may be in part mediated by a direct effect of E2 on vascular smooth muscle cells (VSMCs). Therefore, a series of experiments was performed to determine whether human VSMCs contain a competent E2 receptor, a ligand-activated transcription factor known to mediate E2-induced effects in nonvascular cells.
Methods and Results Ribonuclease protection assays, with a probe derived from the human E2 receptor, were used to demonstrate E2-receptor mRNA in human saphenous vein VSMCs. To show that VSMCs contain E2-receptor protein as well as message, immunoblotting and immunofluorescence studies with a monoclonal anti-E2-receptor antibody were performed, and E2-receptor protein was detected by both methods. Transient transfection assays using a specific E2responsive reporter system were used next to determine whether the VSMC E2 receptor is capable of E2-induced transcriptional transactivation. Initial studies using mammary artery-derived VSMCs resulted in a 2.4-fold increase in reporter activity in response to 10-7 mol/L E2. Subsequent studies using saphenous vein VSMCs demonstrated increasing levels of reporter activation as the concentration of E2 was increased from 10`mol/L (1.3-fold increase; SEM, 0.07; P=.05, n=3) to 10~7 mol/L (1.6-fold increase; SEM, 0.04; P=.002, n=6). The specificity of the E2-induced transactivation of the reporter gene was shown by dose-dependent inhibition of transactivation by the pure E2 antagonist ICI 164,384 and by enhancement of the transactivation by simultaneous overexpression of the E2 receptor.
Conclusions
We have demonstrated for the first time that human VSMCs express E2-receptor mRNA and protein and that the E2 receptor in VSMCs is capable of estrogendependent gene activation. These data suggest a mechanism by which estrogen may directly alter VSMC function. (Circulation. 1994; 89:1943 -1950 Key Words * hormones * smooth muscle * cells . estrogen * genetics C ardiovascular disease is the leading cause of mortality in US women. However, the biology of atherosclerotic disease and ischemic cardiovascular events in women is poorly understood. The low incidence of vascular events in premenopausal women and the marked increase in myocardial infarction following menopause were first recognized more than 50 years ago' and suggested a role for steroid sex hormones in the development of atherosclerosis. Since then, a number of studies have shown that estrogen (E2) administration inhibits the development of experimentally induced atherosclerosis in animal models.2,3 Recent observational studies have demonstrated that oophorectomized women have an increased mortality from cardiovascular disease if they are not given E2 replacement.4 Furthermore, postmenopausal E2 use is associated with a decreased incidence of angiographically documented coronary artery disease,5 myocardial infarction,6 and death from cardiovascular disease.6-9 A recent meta-analysis of the effects of hormonal replacement therapy on mortality in women concluded that postmenopausal E2 replacement reduces the risk of death from cardiac causes by 35%,10 prompting recom-mendations for the widespread use of E2 replacement therapy. 1, 112 The atheroprotective effects of E2 are generally believed to be due to E2-induced changes in classic cardiovascular risk factors. For example, E2 use has been associated with increased high-density lipoprotein levels,5'13,14 decreased low-density lipoprotein levels,5 13 and improved glucose metabolism with decreased serum insulin levels.13 Acute E2 administration has recently been shown to prevent impairment of endothelium-dependent dilation of atherosclerotic arteries in a primate model, suggesting a direct effect of E2 on vascular reactivity.15 However, the mechanism mediating this effect is not yet clear. A number of animal studies have demonstrated specific binding of E2 to vascular cells,16-20 supporting the hypothesis that vascular tissue is E2 sensitive. These studies have relied primarily on detection of intravenously injected radiolabeled hormone in vascular tissues. However, the nature of the E2-binding proteins present, the cells responsible for hormone binding, and direct biological effects of E2 on specific vascular cells have not yet been characterized.
Most of the biological effects of steroid hormones are mediated through intracellular hormone receptors that act as ligand-activated transcription factors (reviewed in References 21 through 23). In the presence of ligand, the estrogen receptor (E2 receptor) binds in a highly specific fashion to DNA containing a cis-acting transcriptional enhancer (the E2-response element [ERE]24), resulting in an altered pattern of gene expression (reviewed in References 25 through 27). The E2-receptor gene has been cloned and sequenced28 and codes for a 66-kd zinc finger protein containing hormone binding, DNA binding, and transcriptional activation domains (reviewed in Reference 22) . This receptor has been shown to upregulate or downregulate the expression of several important genes, including c-myc,29 cyclin,30 neis31 progesterone receptor,32 and HSP2733 in an E2-dependent fashion.
Vascular smooth muscle cells (VSMCs) are one of several cell types within vascular tissue that play a critical role in the pathogenesis of atherosclerosis. VSMC proliferation, induced and sustained by a complex array of growth factors, is the hallmark of myointimal hyperplasia and lesion progression (reviewed in Reference 34) . Because of the importance of VSMC proliferation in the development of atherosclerosis and the known growth-regulatory effects of E2 on several cell types,35-39 we hypothesized that the atheroprotective effect of E2 may be in part mediated by a direct effect of E2 on VSMCs. To begin to explore this hypothesis, we undertook a series of experiments to determine whether human VSMCs contain transcriptionally competent E2 receptor. The results we present establish the presence of both E2-receptor mRNA and protein in human VSMCs and demonstrate further, using transient transfection assays, the functional competence of the E2 receptor in VSMCs.
Methods Cell Culture Techniques
VSMCs were cultured from surgical specimens of human saphenous vein and mammary artery essentially as described.40 For all experiments, VSMCs were grown in media that did not contain phenol red because of the recognized estrogenic effects of this compound.37 Cells were maintained in DMEM containing 10% fetal bovine serum in which the E2 content was determined to be less than 2.6x10-11 mol/L (Hyclone). VSMCs were allowed to migrate from the primary explants and were subsequently passaged at confluence. Cultured cells were a uniform population of smooth muscle cells identified both by their morphology and by immunostaining for smooth muscle-specific a-actin (Sigma Chemical Co; data not shown). VSMCs were harvested at passage 2 for all experiments described below. MCF-7 human breast tumor cells (kindly provided by M. Brown), used as a positive control in several experiments because they are known to express high levels of E2 receptor,41,42 were maintained in DMEM and 10% fetal bovine serum.
RNase Protection Assay
Total cellular RNA was harvested by a commercially available guanidinium thiocyanate method according to the manufacturer's instructions (Biotecx Laboratories). A radiolabeled RNA probe, complementary to 123 base pairs (bp) of the E region (hormone-binding domain) of the human E2-receptor sequence, was constructed by in vitro transcription (Maxi-Script, Ambion) and gel purified on 5% SDS-polyacrylamide gels. RNase protection assays were performed with a commercially available kit (RPAII, Ambion) according to the manufacturer's instructions. The products of the RNase digestion were resolved on 5% SDS-polyacrylamide gels, and relative intensities of protected E2-receptor probe fragments were quantified using the volume integration mode on a Phosphor-Imager (Molecular Dynamics).
Western Blotting
VSMCs were suspended by gentle scraping and lysed in the following buffer: 20 mmol/L Tris (pH 7.4), 50 mmol/L NaCl, 50 mmol/L NaF, 50 mmol/L EDTA, 20 mmol/L Na pyrophosphate, 1 mmol/L Na orthovanadate, 1% Triton X-100, 1 mmol/L PMSF, 0.6 mg/mL leupeptin, and 10 ,g/mL aprotinin.
The lysis buffer was supplemented with both EDTA and multiple protease inhibitors to prevent the partial proteolysis of the E2-receptor protein observed in preliminary studies. To fractionate subcellular components, total lysates were centrifuged at 16 OOOg for 10 minutes, and aliquots of the supernatant and cell pellet were solubilized in a high salt buffer (10% SDS, 500 mmol/L NaCI21) and subjected to SDS-PAGE on 10% gels. Immunoblotting was performed with a well-characterized monoclonal anti-E2-receptor antibody (D547), specific for mammalian E2 receptor43 (kindly provided by G. Greene), that was developed by Enhanced Chemiluminescence (ECL, Amersham).
Immunofluorescent Staining
Immunofluorescent staining of human saphenous VSMCs (HSVSMCs) grown from explants onto glass coverslips was performed using minor modifications of an established protocol. 44 Briefly, cells were fixed in 3.7% formaldehyde, incubated for 1 hour with D547 anti-E2-receptor antibody43 (1: 5 to 1:10 dilutions), washed, exposed to FITC-labeled goat anti-rat IgG (Boehringer-Mannheim) (1:20 to 1:100 dilutions), and examined by fluorescence microscopy. Control studies in which primary antibody was omitted were included in all immunofluorescent studies and were consistently negative (data not shown).
Transfection Assays
Transfection conditions for VSMCs were optimized during preliminary experiments by counting 3-galactosidase-positive cells after transfection with a constitutively expressed (-galactosidase gene (data not shown). The reporter plasmids ERE-Luc (containing three copies of the Xenopus vitellogenin ERE24 proximal to the thymidine kinase promoter driving expression of firefly luciferase cDNA)45 or TK-Luc (identical to ERE-Luc but lacking the ERE; both plasmids were the kind gift of C. Glass) were electroporated (BioRad, Gene Pulser; 220 V, 960 1,F) into cells obtained from one subconfluent T-150 flask. In a subset of experiments, co-transfection of either the expression plasmid pHEGO,46 which contains the wild-type human E2-receptor cDNA driven by an SV-40 enhancer element (kind gift of M. Brown), or an equal quantity of carrier DNA (salmon sperm DNA), was used to determine the effect of overexpression of E2 receptor on the activity of the reporter plasmids. To maintain identical levels of transfection for each experimental condition within an assay, cells pooled from a single electrophoration were aliquoted evenly into a 12-well plate in the presence of 5 mmol/L butyric acid. Thirty-six hours after transfection, the cells were treated with media in the presence or absence of either 17p-estradiol (Sigma Chemical Co) or the pure E2 antagonist ICI 164,38447 (Zeneca Pharmaceuticals; kind gift of A. Wakeling), each dissolved in ethanol. Control cells were treated with ethanol alone to a concentration identical to that of treated cells (final concentration of ethanol, <0.05%). After 
Results

HSVSMCs Express the E2-Receptor Gene
To demonstrate the presence of E2-receptor message in VSMCs, an RNase protection assay was performed with total RNA prepared from HSVSMCs and a riboprobe from the hormone-binding domain of the E2 receptor. RNase protection assays were used rather than Northern blots because of the anticipated low abundance of the E2-receptor message in nonreproductive tissue.49 In Fig 1, the appearance of a 123-bp protected fragment (arrowhead) demonstrates the presence of E2-receptor mRNA in HSVSMCs. MCF-7 breast cancer cell RNA was included in the assay as a positive control and also protected the riboprobe (Fig  1) . Yeast RNA (free of human E2-receptor mRNA) served as a negative control and did not protect the riboprobe (data not shown). Quantification of the intensity of the signal for E2-receptor mRNA demonstrated 42to 53-fold less E2-receptor message in HSVSMCs than in MCF-7 cells, consistent with the known supraphysiological expression of E2 receptor in these tumor cells.42
HSVSMCs Contain E2-Receptor Protein
To demonstrate that VSMCs contain E2-receptor protein as well as message, we analyzed lysates of HSVSMCs by Western blotting with monoclonal anti-E2-receptor antibody. The presence of E2-receptor protein in HSVSMCs is demonstrated in Fig 2. E2-receptor protein was detected consistently by immunoblotting in HSVSMCs derived from both male and female donors and in one study with lysates from VSMCs derived from mammary artery (data not shown). To determine the subcellular distribution of E2-receptor protein in VSMCs, cell lysates were solubilized with high salt conditions used classically to define nuclear and nonnuclear compartmen- talization of steroid hormone receptors.21 The E2-receptor protein was recovered predominantly from the nuclear pellet (Fig 2) . In all such studies, MCF-7 cell protein lysates were used as a positive control in adjacent lanes and produced a band identical in size to that seen in the VSMCs (data not shown). A larger, 72-kd band of unknown identity was seen in some experiments (Fig 2, nuclear pellet lane), as reported in other cells.50 E2receptor protein was also found by immunoblotting with a different anti-E2-receptor monoclonal antibody (D7543; kindly provided by G. Greene; data not shown).
To confirm the subcellular distribution of the E2 receptor observed by immunoblotting, immunofluorescent staining for E2 receptor was also undertaken. Fig 3 shows both the phase-contrast appearance (panel A) and immunofluorescent staining for E2 receptor (panel B) in freshly cultured HSVSMCs. The predominantly nuclear localization of E2 receptor in HSVSMCs is consistent with the pattern observed in similar immunohistochemical studies of E2 receptor in other nonvascular cells.43.5'-53 Control studies in which nonimmune serum was substituted for primary antibody demonstrated only faint and diffuse background staining (data not shown).
E2 Receptor in Human VSMCs Is Transcriptionally Competent
The data presented thus far demonstrate that VSMCs contain both E2-receptor mRNA and protein but do not establish the functional integrity of the receptor. To determine whether the human VSMC E2 receptor is capable of specific, E2-induced transcriptional transactivation, the E2 responsive reporter plasmid ERE-Luc or the control plasmid TK-Luc was introduced into human VSMCs. Exposure of VSMCs derived from mammary arteries to 10`mol/L E2 had no effect on the activity of the TK-Luc plasmid, which lacks the ERE (Fig 4) . However, exposure of VSMCs derived from mammary arteries to 10-7 mol/L E2 resulted in a 2.4-fold increase in the activity of the ERE-Luc plasmid (Fig 4) . E2 also induced increases in ERE-driven luciferase activity in experiments using saphenous vein VSMCs derived from several different donors. The induction of reporter activity in HSVSMCs increased in a dose-dependent fashion, from 1.3-fold (SEM, 0.07;
P=.05, n=3) at 10`mol/L E2 to 1.6-fold (SEM, 0.04; P=.002, n=6) at 10-7 mol/L E2 (Fig 4) . These data provide direct evidence for the functional integrity of endogenous E2 receptor in VSMCs.
To define further the specificity of the E2-induced activation of the ERE in VSMCs, a separate series of competition experiments was conducted with E2 and the pure antiestrogen ICI 164,384. In mammary arteryderived VSMCs transfected with the ERE-Luc plasmid, 10-7 mol/L E2 activated the ERE 1.5-fold in the presence of low-dose (10-7 mol/L) ICI 164,384 ( Fig 5,  P=.01 ). Treatment with increasing doses of ICI 164,384 led to a dose-dependent inhibition of the E2-induced transactivation, which was complete at 10-5 mol/L ICI 164,384 ( Fig 5) . These data are consistent with the relative potencies of E2 and ICI 164,384 previously reported54 and directly support the specificity of the E2-mediated transactivation of the ERE reporter (see 'Discussion"). Treatment with ICI 164,384 alone had no effect on the activity of the plasmid TK-Luc, which lacks the ERE (data not shown).
Taken together, these data demonstrate that human VSMCs contain E2 receptor with transcriptional activation that is specifically regulated by E2, although the magnitude of the transactivation of the reporter system absence of overexpression of the E2 receptor, treatment of HSVSMCs with iO-`mol/L E2 again resulted in a 1.5-fold increase in ERE activity (Fig 6; cf Fig 4) . However, in HSVSMCs co-transfected with the E2receptor expression plasmid, E2 exposure resulted in a 7.5-fold increase in ERE activity (Fig 6) . Of note, co-transfection of the E2-receptor plasmid had no effect on the activity of the TK-Luc (control) plasmid ( Fig 6) . activity. Bars represent the mean luciferase activity relative to control cells that were not exposed to E2 (+SEM). Note that overexpression of the E2 receptor enhances E2-induced activation of the E2-response element reporter (ERE-Luc) fivefold but has no effect on the control plasmid (TK-Luc) lacking this element.
Discussion
The data presented here demonstrate for the first time that human VSMCs contain the biochemical machinery known to mediate E2 effects on the transcription of E2-responsive genes in E2-responsive tissues. 55 The results demonstrate E2-receptor mRNA by RNase protection assay and E2-receptor protein by both Western blotting and immunofluorescent staining in HSVSMCs. Furthermore, the majority of VSMC E2 receptor is shown to be localized to the nucleus by both immunoblotting (Fig 2) and immunofluorescence ( Fig  3) , although some cytosolic receptor was also detected. These findings are consistent with other immunologically based detection methods demonstrating E2 receptor primarily in the nucleus of nonvascular cells. 43, [51] [52] [53] [54] Although the data presented above demonstrate that human VSMCs contain E2 receptor, they also suggest that the receptor is present at a low level. The RNase protection assay demonstrates that E2-receptor mRNA is approximately 50-fold less abundant in HSVSMCs than in MCF-7 breast cancer cells. In addition, several lines of evidence suggest that E2-receptor protein levels were substantially less in HSVSMCs than in MCF-7 cells; preliminary experiments demonstrated that E2receptor protein was difficult to detect by non-ECLbased immunoblotting techniques, and compared with MCF-7 cells, lysates containing 25to 50-fold more VSMCs were required for detection of E2 receptor by immunoblotting (R.H. Karas, M.E. Mendelsohn, unpublished observations). Finally, the E2-receptor overexpression studies, demonstrating that co-transfection of an E2-receptor expression plasmid increases the magnitude of E2-induced activation of the ERE in VSMCs (Fig 6) , further support the conclusion that VSMCs contain a relatively low abundance of functional E2 receptor.
Demonstration of E2-receptor mRNA and protein in a cell is not sufficient to establish the functional integrity of the receptor in that cell because of the complex regulatory system controlling transcriptional activation of steroid hormone receptors. A number of intracellular events are known to modulate steroid hormone receptor function. For example, several proteins have been found to associate with estrogen and other steroid receptors.23-56-61 Some such interactions appear to be critical for efficient transactivation of steroid-responsive genes,62 whereas others may inhibit transcriptional activation.57-59 Thus, cells may contain E2 receptor in a transcriptionally inefficient or inactive state due to interactions with and/or absence of associated proteins. The transient transfection assays presented in Figs 4 through 6 demonstrate conclusively that the E2 receptor in human VSMCs is transcriptionally competent. The specificity of the E2-induced transactivation in VSMCs is demonstrated by (1) control studies with the control plasmid TK-Luc, which establish that the ERE is necessary for transactivation of the reporter; (2) the dose-dependent increase in transactivation ofERE-Luc by E2; and (3) dose-dependent inhibition of the E2-induced increase in ERE-driven reporter activity by the specific E2 antagonist ICI 164,384. VSMC proliferation is a central event in atherosclerosis and may have a different biology in women than in men. Demonstration that VSMCs contain functional E2 receptor raises the possibility that E2 may alter patterns Circulation Vol 89, No 5 May 1994 of gene expression important to VSMC growth. E2 can promote or inhibit proliferation, depending on the type of cell studied. Both neuroblastoma cells and 3T3 fibroblasts transfected with E2-receptor expression vectors are growth suppressed by exposure to E2,35.63 and E2 has been reported to inhibit the growth of VSMCs derived from rabbit aorta,6" rat pulmonary artery,65 and porcine coronary artery.68 These studies and the known atheroprotective effect of estrogen in postmenopausal women are consistent with the hypothesis that in some settings E2 may directly inhibit the proliferation of VSMCs. Although our data demonstrate E2-induced activation of an exogenous ERE in VSMCs, it will be important next to demonstrate that E2 directly activates the expression of endogenous VSMC genes. In nonvascular cells, only a few E2 receptor-activated genes have thus far been identified, including HSP27, the progesterone receptor, c-fos, and c-myc.23'32'67'68 If E2 directly modulates the growth response of VSMCs, the protooncogenes are candidate genes whose expression may be modulated by estrogen.
How might the VSMC E2 receptor mediate a growthinhibitory effect of E2? One logical target for E2mediated growth regulation is proto-oncogene expression. E2-dependent regulation of the expression of proto-oncogenes is well described in breast cancer cells.29'31'69 Some of the proto-oncogenes known to be regulated by E2 in breast cancer cells (eg, c-myc29,67) are also important regulators of VSMC proliferation.70,71 Another mechanism by which steroid receptors might participate in growth control is suggested by recent reports demonstrating cross-talk between steroid hormone receptor and cell surface receptor-mediated signaling pathways.39'59'60'72-75 Steroid and cell surface receptor-mediated signaling may interact in several ways. For example, steroid receptors may be activated directly by mitogens that act through membrane-spanning receptors, as in the recent report of epidermal growth factor-induced transactivation of an ERE-reporter system in endometrial adenocarcinoma cells.76 In addition, steroid receptors may have complex interactions with other transcription factors known to regulate proliferation, such as those between the glucocorticoid receptor and the c-fos protein. 58-60'68 The E2 receptor has also been shown to interact specifically with AP-1.77,78 Such studies raise the intriguing possibility that E2 receptormediated effects on gene expression in VSMCs may converge in several ways with growth factor-mediated pathways known to regulate the proliferation of VSMCs, a critical component in the pathogenesis of atherosclerosis.4
In summary, we have demonstrated for the first time that human VSMCs express E2-receptor mRNA and protein and have shown further that E2 receptor in VSMCs is capable of transcriptional transactivation. Human VSMCs therefore possess the requisite biochemical machinery to respond directly to E2 exposure. Our model provides a novel system with which to study the role of estrogen and the estrogen receptor in VSMC biology. Given the expanding investigations into the role of antiestrogens in the treatment of breast cancer, the controversy regarding the cardiovascular effects of ical effects of E2 on VSMCs may also have important clinical implications.
